Mohammad Kadivar

affiliated with the university

Research areas and keywords

UKÄ subject classification

  • Immunology in the medical area

Keywords

  • inflammatory bowel disease

Research

Inflammatory Bowel Disease (IBD) is defined as chronic-relapsing inflammation of the gastrointestinal tract, not resulting from specific pathogens. IBD is a major cause of lifetime morbidity and has a prevalence of approximately 1%, a number steadily increasing for unknown reason. The two main types of IBD are Ulcerative colitis (UC) and Crohn's disease (CD). The etiology of IBD has not been defined, but most likely involves a complex interaction of genetic, environmental, and immunoregulatory factors. A widely accepted working hypothesis on the pathogenesis of IBD is that an inadequately aggressive acquired T lymphocyte response to a subset of commensal enteric bacteria arises in genetically predisposed hosts.

 

Aims: The overall aim is to investigate the role of mucosal leukocytes compartment in IBD.

 

Specific aims:

 

1) Characterization of mucosal T cell subsets in inflammatory bowel diseases (IBD).

It has been shown that both pro-inflammatory and regulatory T cells infiltrate into the inflamed tissue. It is then important to understand and examine the balance between inflammatory and regulatory T cells in the healthy control and compare it to inflamed tissue.

 

2) Cellular and molecular mechanisms of mucosal healing in patients with Crohn's disease (CD).

Anti-TNFα antibody treatment has revolutionized the management of Crohn’s disease (CD). Growing evidence suggests that achieving mucosal healing can improve patient outcomes and, potentially, alter the course of the disease. Compared to treatment with corticosteroids or other commonly used anti-inflammatory agents in CD patients, the anti-TNFα agents are substantially more potent in inducing mucosal healing. However, the reasons for this are unknown and, somewhat surprisingly, also the exact anti-inflammatory mechanisms of anti-TNFα therapy remain elusive.

 

3) Characterization of human CD8alpha–beta gamma–delta T lymphocytes.

We described for the first time a novel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface, while γδ T-cells have been divided into CD8αα+ and CD8- T-cells. We found that CD8αβ+ γδ T-cells constitute a novel lymphocyte subset which is strongly enriched within the gut and may play an important role in gut homeostasis and mucosal healing in IBD.

 

4) Introduction of new intestinal inflammation index.

The disease activity in IBD has been evaluated through describing the symptoms. However, symptoms correlate poorly to the level of inflammation in the gut. The purpose of this study is to generate a new clinically useful and improved immunohistological score for clinical management of patients with IBD by introducing an automated and quantitative inflammatory scoring system for defining the degree of inflammation as well as a qualitative inflammatory pattern index for characterization of the disease subtypes.

Recent research outputs

Viktoria Bergqvist, Mohammad Kadivar, Molin, D., Angelison, L., Hammarlund, P., Olin, M., Torp, J., Olof Grip, Nilson, S., Hertervig, E., Lillienau, J. & Marsal, J., 2018, In : Therapeutic Advances in Gastroenterology. 11, 175628481880124.

Research output: Contribution to journalArticle

Löfroos, A-B., Mohammad Kadivar, Lindehammer, S. & Marsal, J., 2017 Oct 11, In : European Journal of Medical Research. 22, 1, 40.

Research output: Contribution to journalArticle

Mohammad Kadivar, 2017, Lund: Lund University, Faculty of Medicine. 104 p.

Research output: ThesisDoctoral Thesis (compilation)

View All (5)